Ischemia and reperfusion (I/R) induces neutrophil infiltration in skeletal muscle that is localized to the ischemic region. To transmigrate at ischemic regions, granulocytes must first arrest in the postcapillary venular segment of the microcirculation. Initially, leukocytes roll along the endothelium of these venules, a weak adhesive interaction that is mediated by the selectins (L-, E-, and P-selectin). Leukocyte rolling functions to slow the neutrophil during its transit through the microcirculation, thereby allowing it to monitor its local environment for the presence of activating factors arising from the ischemic tissues. When activated, the rolling granulocyte is rendered capable of forming the stronger adhesive interactions that allow the cell to become arrested in postcapillary venules in the ischemic region. These adhesive interactions are mediated by a leukocyte glycoprotein complex designated CD11/CD18 and intercellular adhesion molecule-1 (ICAM-1) expressed on endothelial cells. The stationary neutrophil uses the gradient in concentration of soluble chemoattractants liberated from ischemic tissues as a directional cue to move from the vascular to extravascular compartment, being guided in its transit across the endothelium by interactions with platelet endothelial cell adhesion molecule-1 (PECAM-1), an adhesive molecule localized to the interendothelial cleft. This paper reviews current understanding of the mechanisms underlying the establishment of leukocyte/endothelial cell interactions in postischemic skeletal muscle in terms of specific adhesion molecules that participate in neutrophil sequestration after I/R. Discovery of the molecular determinants of neutrophil/endothelial cell adhesion has uncovered potential mechanisms whereby agents exhibiting anti-adhesive properties may act. The micronized purified flavonoid fraction (450 mg diosmin, 50 mg hesperidin) prevents I/R-induced leukocyte adhesion in skeletal muscle. This anti-adhesive effect appears to be mediated at least in part by inhibition of induced expression of ICAM-1.

1.
Gute D, Korthuis RJ: Role of leukocyte adherence in reperfusion-induced microvascular dysfunction and tissue injury; in Granger DN, Schmid-Schönbein GW (eds): Physiology and Pathophysiology of Leukocyte Adhesion. New York, Oxford University Press, 1995, pp 359–380.
2.
Panes J, Granger DN: Leukocyte-endothelial cell interactions: Molecular mechanisms and implications in gastrointestinal disease. Gastroenterology 1998;114:1066–1090.
3.
Rubin BB, Romaschin A, Walker PM, Korthuis RJ: Mechanisms of postischemic injury in skeletal muscle: Intervention strategies. J Appl Physiol 1996;81:369–387.
4.
Lipowsky HH: Leukocyte margination and deformation in postcapillary venules; in Granger DN, Schmid-Schönbein GW (eds): Physiology and Pathophysiology of Leukocyte Adhesion. New York, Oxford University Press, 1995, pp 130–147.
5.
Atherton A, Born GVR: Relationship between the velocity of rolling granulocytes and that of blood flow in venules. J Physiol (Lond) 1973;233:157–165.
6.
Zimmerman GA, Prescott SM, McIntyre TM: Endothelial cell interactions with granulocytes: Tethering and signaling molecules. Immunol Today 1992;13:93–100.
7.
Beilacqua MP, Nelson RM: Selectins. J Clin Invest 1993;91:379–387.
8.
Tedder TF, Steeber DA, Chen A, Engel P: The selectins:Vascular adhesion molecules. FASEB J 1995;9:866–873.
9.
Forrest M, Paulson JC: Selectin family of adhesion molecules; in Granger DN, Schmid-Schönbein GW (eds): Physiology and Pathophysiology of Leukocyte Adhesion. New York, Oxford University Press, 1995, pp 43–82.
10.
Jutila MA, Rorr L, Berg EL, Butcher EC: Function and regulation of the neutrophil MEL-14 antigen in vivo: Comparison with LFA-1 and MAC-1. J Immunol 1989;143:3318–3324.
11.
Ichikawa H, Flores S, Kvietys PR, Wolf RE, Yoshikawa T, Granger DN, Aw TY: Molecular mechanisms of anoxia/reoxygenation-induced neutrophil adherence to cultured endothelial cells. Circ Res 1997;81:922–931.
12.
Baumheuter S, Singer MS, Henzel W, Hemmerich S, Renz M, Rosen SD, Lasky LA: Binding of L-selectin to the vascular sialomucin CD34. Science 1993;262:436–438.
13.
Picker LJ, Warnock RA, Burns AR, Doerschuk CM, Berg EL, Butcher EC: The neutrophil selectin LECAM-1 presents carbohydrate ligands to the vascular selectins ELAM-1 and GMP-140. Cell 1991;66:921–933.
14.
Moore KL, Stults NL, Diaz S, Smith DF, Cummings RD, Varki A, McEver RP: Identification of a specific glycoprotein ligand for P-selectin (CD62) on myeloid cells. J Cell Biol 1992;118:445–456.
15.
Moore KL, Patel KD, Bruehl RE, Li F, Johnson DA, Lichenstein HS, Cummings RD, Bainton DF, McEver RP: P-selectin glycoprotein ligand 1 mediates the rolling of human neutrophils on P-selectin. J Cell Biol 1995;128:661–671.
16.
Anderson DC: The role of β2 integrins and intercellular adhesion molecule type 1 in inflammation; in Granger DN, Schmid-Schönbein GW (eds): Physiology and Pathophysiology of Leukocyte Adhesion. New York, Oxford University Press, 1995, pp 3–42.
17.
Wakelin MW, Sanz MJ, Dewar A, Albelda SM, Larkin SW, Boughton-Smith N, Williams TJ, Nourshargh S: An anti-platelet-endothelial cell adhesion molecule 1 antibody inhibits leukocyte extravasation from mesenteric microvessels in vivo by blocking the passage through the basement membrane. J Exp Med 1996;184:229–239.
18.
Romer LH, McLean NV, Yan HC, Daise M, Sun J, De Lisser HM: IFN-γ and TNF-α induced redistribution of PECAM-1 (CD31) on human endothelial cells. J Immunol 1995;154:6582–6592.
19.
Berman ME, Muller WA: Ligation of platelet/endothelial cell adhesion molecule 1 (PECAM-1/CD31) on monocytes and neutrophils increases binding capacity of leukocyte CR3 (CD11b/CD18). J Immunol 1995;154:299–307.
20.
Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T: Tanscriptional regulation of endothelial cell adhesion molecules: NF-κB and cytokine-inducible enhancers. FASEB J 1995;9:899–909.
21.
Read MA, Whitley MZ, Williams AJ, Collins T: NF-κB and IκB α: An inducible regulatory system in endothelial activation. J Exp Med 1994;179:503–512.
22.
Roebuck KA, Rahman A, Lakshminarayanan V, Janakidevi K, Malik AB: H2O2 and tumor necrosis factor-α activate intercellular adhesion molecule-1 (ICAM-1) gene transcription through distinct cis regulatory elements within the ICAM-1 promoter. J Biol Chem 1995;270:18966–18974.
23.
Gute DC, Ishida T, Yarimizu K, Korthuis RJ: Inflammatory responses to ischemia and reperfusion in skeletal muscle. Mol Cell Biochem 1998;179:169–187.
24.
Akimitsu T, Gute DC, Korthuis RJ: Preconditioning prevents postischemic leukocyte adherence and emigration. Am J Physiol 1996;271:H2052–H2059.
25.
Korthuis RJ, Gute DC: Molecular determinants of leukocyte/endothelial cell adhesion in postischemic skeletal muscle: Effect of S 5682, a micronized flavonoid. J Pharmacol Exp Ther, submitted.
26.
Wang C, Kerrigan CL, Stotland MA: Kinetics of E-slectin expression in surgical flaps. Plast Reconstr Surg 1997;100:1482–1488.
27.
Seekamp A, Till GO, Mulligan MS, Paulson JC, Anderson DC, Miyasaka M, Ward PA: Role of selectins in local and remote tissue injury following ischemia and reperfusion. Am J Pathol 1994;144:592–598.
28.
Lerond L: Action of Daflon 500 mg on the principal inflammatory mediators. Phebology 1994;9(suppl 1):34–39.
29.
Friesenecker B, Tsai AG, Intaglietta M: Cellular basis of inflammation, edema, and the activity of Daflon 500 mg. Int J Microcirc 1995;15(suppl 1):17–21.
30.
Bouskela E, Donyo KA, Verbeuren TJ: Effects of Daflon 500 mg on increased microvascular permeability in normal hamsters. Int J Microcirc 1995;14(suppl 1):22–26.
31.
Korthuis RJ, Gute DC: Postischemic leukocyte/endothelial cell interactions and microvascular barrier dysfunction in skeletal muscle: Cellular mechanisms and the effect of Daflon 500 mg. Int J Microcirc 1997;17(suppl 1):11–17.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.